STERIS plc

(New York Stock Exchange)
Back to all articles
Bullish +75

STERIS' Q4 2026 Earnings: What to Expect

AI-generated analysis

πŸ₯ STERIS (STE) is a Mentor, Ohio-based company providing infection prevention products and services.

πŸ’° The firm currently has a market capitalization of $22.2 billion.

πŸ“… Analysts anticipate the company will report its fiscal fourth-quarter 2026 earnings soon.

πŸ€‘ EPS expectations for Q4 include a profit of $2.89 per share, representing a 5.5% increase from last year.

πŸ“ˆ STE has matched or beat consensus estimates in each of the last four quarters.

🎯 Full-year analysts project an EPS of $10.22, which is up 10.9% from fiscal 2025.

πŸš€ Long-term projections show EPS rising to $11.04 in fiscal 2027, an 8% year-over-year increase.

πŸ“‰ Despite recent market gains, STE stock has underperformed the S&P 500 and Health Care ETF over the past 52 weeks.

πŸ“… Previous Q3 results on Feb. 4 showed revenue of $1.50 billion, surpassing estimates.

⭐ Wall Street sentiment remains bullish with a "Moderate Buy" rating and significant upside potential.

πŸ‘¨β€πŸ’Ό Five out of eight analysts covering the stock advise a "Strong Buy" rating while three recommend "Hold."

πŸ’΅ The average analyst price target is $287.33, implying a 30.9% potential upside from current levels.

⚠️ Disclosure indicates author Neha Panjwani held no direct or indirect positions in the securities mentioned.

Bullish Signals
  • STERIS is expected to report a profit of $2.89 per share on a diluted basis in Q4 2026, representing a 5.5% increase from the year-ago quarter's $2.74 per share.
  • The company has consistently beaten or matched consensus estimates in each of the last four quarters, demonstrating reliable performance.
  • For fiscal 2026, analysts project STE to report an EPS of $10.22, which is a 10.9% increase from $9.22 in fiscal 2025.
  • Forward guidance looks strong with expected EPS rising 8% year-over-year to $11.04 in fiscal 2027.
  • The recent Q3 earnings on Feb. 4 saw STE shares close up by 1%, with revenue of $1.50 billion surpassing analyst estimates of $1.48 billion.
  • Wall Street consensus is bullish on the stock, with five out of eight analysts rating it as a 'Strong Buy' and an overall 'Moderate Buy' rating.
  • The average analyst price target is set at $287.33, indicating a notable potential upside of 30.9% from current levels.
Risk Factors
  • STERIS stock has significantly underperformed the broader market, trailing the S&P 500 Index's 33.6% gains over the past 52 weeks with only marginal share appreciation.
  • The company also lagged behind its specific sector peers, failing to capture the State Street Health Care Select Sector SPDR ETF's (XLV) 10.1% gains during the same period.
  • Despite generally bullish analyst ratings, three out of eight analysts covering STE have given a "Hold" rating rather than a buy recommendation.
Full Analysis
STERIS plc (STE), a Mentor, Ohio-based provider of infection prevention products and services with a market capitalization of $22.2 billion, is preparing to announce its fiscal fourth-quarter 2026 earnings. The company specializes in manufacturing and distributing sterilizers, washers, surgical tables, lights, equipment management systems, and endoscopy accessories. Ahead of the quarterly report, analysts project a diluted earnings per share (EPS) of $2.89 for Q4 2026, representing a 5.5% increase from the $2.74 EPS reported in the year-ago quarter. Historically, STE has either beaten or matched consensus estimates in each of its last four quarters, contributing to a generally bullish analyst sentiment. Looking at the full-year and subsequent fiscal projections, analysts anticipate STE will report an annualized EPS of $10.22 for fiscal 2026, up 10.9% from $9.22 in fiscal 2025. The forward outlook suggests further growth, with EPS expected to rise 8% year over year to $11.04 in fiscal 2027. Recent performance indicates the stock has underperformed broader market benchmarks; specifically, STE shares have gained marginally over the past 52 weeks compared to the S&P 500 Index’s 33.6% gains and the State Street Health Care Select Sector SPDR ETF’s (XLV) 10.1% gains during the same period. Notably, on February 4, STE shares closed up by 1% after reporting Q3 results where revenue reached $1.50 billion, surpassing analyst estimates of $1.48 billion, while adjusted EPS of $2.53 met Wall Street forecasts. Investor sentiment remains positive with an overall "Moderate Buy" rating among eight covering analysts; five recommend a "Strong Buy" and three rate it as "Hold." The average analyst price target is set at $287.33, indicating a potential upside of 30.9% from current levels. In the recent quarter mentioned, the company continued to align with financial expectations regarding revenue and earnings adjustments. All information provided in this article serves informational purposes, noting that the author did not hold positions in the securities discussed at the time of publication.